Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 7/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403895 | 0.91 | SLC16A1 (0.58) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5403281 | 0.89 | SLC16A1 (0.70) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5413437 | 0.86 | SLC16A1 (0.56) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6993946 | 0.85 | SLC16A1 (0.54) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL7057842 | 0.84 | SLC16A1 (0.79) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5402703 | 0.83 | SLC16A1 (0.54) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5405605 | 0.82 | SLC16A1 (0.51) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5411108 | 0.78 | SLC16A1 (0.45) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864693 | 0.77 | SLC16A1 (0.80) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6990753 | 0.77 | SLC16A1 (0.55) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975636-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONES AS T-CELL PROLIFERATION INHIBITORS | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | claimed |
| EP-0975636-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | claimed |
| WO-1998046606-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-22 | — | — | WO | claimed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| EP-0975636-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONES AS T-CELL PROLIFERATION INHIBITORS | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| US-6028074-A | FOR TREATING ALLOGRAFT REJECTION | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-02-22 | — | — | US | disclosed |
| EP-0975636-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046606-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SLC16A1 4140/4885CYP2C9 82/4885MAPKAPK2 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.